Similar Search Results

Pharmaceutical Policy, 2002

eSocialSciences - 2005

Pharmaceutical Policy of 2002 covering issues of pricing, ,marketing, size of market, quality, production, investment, regulatory authority, monitoring, ethical issues

Persistent link: https://www.econbiz.de/10009250530

Pharmaceutical Patent Term Restoration in New Zealand

Parker, John - In: Prometheus 18 (2000) 3, pp. 319-326

This paper draws attention to the 1998 legislation in Australia which introduced a drug - specific patent term restoration procedure called a supplementary protection certificate. After investigating effective patent life data the results suggest that there is a case for such a measure in New...

Persistent link: https://www.econbiz.de/10009275787

Diffusion of New Drugs in the Post-TRIPS Era

Berndt, Ernst; Blalock, Nathan; Cockburn, Iain - In: International Journal of the Economics of Business 18 (2011) 2, pp. 203-224

We examine the international diffusion of new drugs under the post-TRIPS intellectual property rights regime. Even after controlling for drug characteristics and variation in national health expenditure, we find substantial differences across countries in the probability of a drug being...

Persistent link: https://www.econbiz.de/10009275834

The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection

Grabowski, Henry - In: International Journal of the Economics of Business 18 (2011) 2, pp. 161-176

The pharmaceutical industry has an outstanding record of innovative performance over the past 50 years. The R&D process has become more knowledge-based and a market for innovation has emerged between research start-ups, development-stage firms, and the larger, multinational companies. At the...

Persistent link: https://www.econbiz.de/10009275870

Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation

Berndt, Ernst; Aitken, Murray - In: International Journal of the Economics of Business 18 (2011) 2, pp. 177-201

We examine market share and price trends in the quarter century since the 1984 Waxman-Hatch legislation. The generic share of US retail prescriptions has grown from 18.6% in 1984 to 74.5% in 2009, with a notable acceleration in recent years. Whereas in 1994 the generic price index fell from 100...

Persistent link: https://www.econbiz.de/10009275875

Vaccine Supply: Effects of Regulation and Competition

Danzon, Patricia; Pereira, Nuno Sousa - In: International Journal of the Economics of Business 18 (2011) 2, pp. 239-271

In US vaccine markets, competing producers with high fixed, sunk costs face relatively concentrated demand. The resulting price and quality competition leads to the exit of all but one or very few producers per vaccine. Our empirical analysis of exits from US vaccine markets supports the...

Persistent link: https://www.econbiz.de/10009276800

Income Based Price Subsidies and Parallel Imports

Acharyya, Rajat; Garcia-Alonso, Maria D.C. - School of Economics, University of Kent - 2010

We present a policy game where a Rich country has a higher capacity than a Poor country to commit to certain elements of health policy such as providing income related price subsidies and allowing parallel imports (PI). When allowing PI is not a choice for the Poor country, the Rich country...

Persistent link: https://www.econbiz.de/10008693046

Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico

Santiago-Rodriguez, Fernando; Dutrenit, Gabriela - United Nations University, Maastricht Economic and … - 2010

Interactive learning, particularly between firms and public research organizations (PRO), nurtures the dynamics of systems of innovation. Limited interaction contributes to explain poor performance in R&D and ultimately, in innovation by developing countries. But why this is so? Based on...

Persistent link: https://www.econbiz.de/10008693155

Determinants of the United States’ trade of pharmaceuticals.

Boring, Anne - Université Paris-Dauphine

pharmaceuticals in developing countries and should increase trade. The industry argues that other factors are necessary for poor … the United States’ trade of pharmaceuticals? A gravity model using panel data from 1993 to 2007 shows that foreign patent … protection is not a strong determinant of the United States imports and exports of pharmaceuticals. An OLS estimation, a Tobit …

Persistent link: https://www.econbiz.de/10008725961

Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?

Dalen, Dag Morten; Sorisio, Enrico; Strøm, Steinar - CESifo - 2010

TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...

Persistent link: https://www.econbiz.de/10008727300